NCT01235351View on ClinicalTrials.gov

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

PHASE2CompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Myocardial InfarctionPercutaneous Coronary Intervention
Interventions
DRUG

Clopidogrel

Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype

DRUG

Clopidogrel

Clopidogrel 75 mg daily, 150 mg daily

Trial Locations (1)

02115

TIMI Study Group, Boston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

The TIMI Study Group

OTHER